EJHaem · 2026
Glofitamab in Heavily Pretreated Mantle Cell Lymphoma Patients: A Multicenter Real-World Case Series.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rotter Natalia, Raderer Markus, List Agnes, Haslbauer Ferdinand, Saini Olga, Egle Alexander, Magnes Teresa, Leisch Michael, Kaynak Emine, Buxhofer-Ausch Veronika, Casadei Beatrice, Keil Felix, Rumpold Holger, Hess Georg, Greil Richard, Zinzani Pier Luigi, Melchardt Thomas
Аннотация
BACKGROUND: Relapsed or refractory mantle cell lymphoma (r/r MCL) remains difficult to treat despite therapeutic advances.
METHODS: This multicenter retrospective study included 10 patients with r/r MCL treated with glofitamab across five sites in Austria and Italy before European approval (January 2023-May 2024).
RESULTS: Patients were heavily pretreated (median 4.5 prior lines; 5/10 post-CAR-T). After a median of five cycles, responses were observed in 7/9 evaluable patients, including complete response in 4/9. Cytokine-release syndrome occurred in 7/10 (mostly Grade 1-2), including grade 3 events in 2/10, while ICANS occurred in 2/10 patients, including one Grade 4 event. Three patients received glofitamab as bridging therapy and all proceeded to CAR-T infusion.
CONCLUSION: Glofitamab showed encouraging activity and manageable toxicity in heavily pretreated MCL, including as bridging therapy to CAR-T-cell treatment.
TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.
METHODS: This multicenter retrospective study included 10 patients with r/r MCL treated with glofitamab across five sites in Austria and Italy before European approval (January 2023-May 2024).
RESULTS: Patients were heavily pretreated (median 4.5 prior lines; 5/10 post-CAR-T). After a median of five cycles, responses were observed in 7/9 evaluable patients, including complete response in 4/9. Cytokine-release syndrome occurred in 7/10 (mostly Grade 1-2), including grade 3 events in 2/10, while ICANS occurred in 2/10 patients, including one Grade 4 event. Three patients received glofitamab as bridging therapy and all proceeded to CAR-T infusion.
CONCLUSION: Glofitamab showed encouraging activity and manageable toxicity in heavily pretreated MCL, including as bridging therapy to CAR-T-cell treatment.
TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.